Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Breast 1

Conditions

Sarcoma, Ewing 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Fulvestrant 126Trastuzumab 116Paclitaxel 113Letrozole 108pembrolizumab 80palbociclib 76pertuzumab 75Capecitabine 75Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 65exemestane 63Tamoxifen 63ribociclib 61trastuzumab deruxtecan 58Surveys and Questionnaires 51Specimen Handling 51Radiotherapy 50Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 41olaparib 40Standard of Care 36Biopsy 33sacituzumab govitecan 32130-nm albumin-bound paclitaxel 32Exercise 30Doxorubicin 30eribulin 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × romiplostim × 1 year × Clear all
NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen

Phase 3 Active not recruiting
145 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡